Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsSolid TumorsProtocol groupAggressive LymphomasNeuro-OncologyTransplantationDiseaseNHL, CNS-NHLSubgroupICD10C83.3MeSHCentral Nervous System NeoplasmsLymphoma, Non-HodgkinSequenceFreiburg CNS-NHL StudyMATRIXMTRX8000/RITU375/TMZL150, CNS lymphoma, C1 (PID1859) -|- C2 (PID1860) -|- C3 (PID1861) -|- C4 (PID1864) -|- C5 (PID1865) -|- C6 (PID1866)R-MP (RITU375/MTRX3000/PRCR60), CNS Lymphoma, C1 (PID1191) -|- C2-3 (PID1030) -|- PRCR100, maint. (PID1031)RITU375/MTRX3500/PRCR100/VNCR2, CNS lymphoma, C1-3 (PID1896) -|- RITU375/CYTA3000, C4-6 (PID1901)ChemotherapyChemo-substanceCarboplatinCarmustineCytarabineDexamethasoneEtoposideIfosfamideMethotrexateProcarbazineRituximabTemozolomideThiotepaVincristineChemo-substanceCarboplatinCarmustineCytarabineDexamethasoneEtoposideIfosfamideMethotrexateProcarbazineRituximabTemozolomideThiotepaVincristineChemo-substanceCarboplatinCarmustineCytarabineDexamethasoneEtoposideIfosfamideMethotrexateProcarbazineRituximabTemozolomideThiotepaVincristineChemo-substanceCarboplatinCarmustineCytarabineDexamethasoneEtoposideIfosfamideMethotrexateProcarbazineRituximabTemozolomideThiotepaVincristineNo. Substances12345 RadiotherapySupportive therapySupportive substanceAciclovirAmphotericin BAprepitantBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFilgrastimFluconazoleFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPosaconazolePotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAmphotericin BAprepitantBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFilgrastimFluconazoleFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPosaconazolePotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAmphotericin BAprepitantBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFilgrastimFluconazoleFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPosaconazolePotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAmphotericin BAprepitantBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFilgrastimFluconazoleFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPosaconazolePotassium chloridePrednisoloneSodium BicarbonateNo. Substances5689111213141516Protocol classificationTherapy classificationalternativecurrent standardstudy analogIntensityhigh doseStandard doseTherapy indicationFirst lineTherapy phaseautologous stem cell transplantationconditioningConsolidationInductionMaintenanceTherapy intentioncurativedisease controlRisksAnemia Hb below 8g/dlCardiotoxicityDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHepatotoxicityHyperglycemiaHypokalemiaHyponatremiaIncrease AminotransferasesInfectionsLeukopeniaLymphopeniaMucositisNephrotoxicityNeuropathyNeutropeniaPneumonitisPyrexiaRenal FailureThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorFritsch KHouillier CIllerhaus GRubenstein JLDiseaseErstdiagnose eines primären NHL des ZNS, 18-65 Jahreneudiagnostiziertes primäres ZNS-Lymphom, > 60 JahreNeu diagnostiziertes primäres ZNS-Lymphom, > 66 Jahre, Karnofsky > 70neudiagnostiziertes primäres ZNS-Lymphom, > 66 Jahre, Karnofsky > 70neudiagnostiziertes primäres ZNS-Lymphom, ECOG 0-2Neudiagnostiziertes primäres ZNS-Lymphom, ECOG 0-2primäres ZNS-NHL, ErstdiagnoseOriginAlbert-Ludwigs University, Freiburg, Germany, Freiburger ZNS-NHL ProtokollDepartment of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Primain StudyHelen Diller Comprehensive Cancer Center, University of California, San Francisco, CALGB 50202 (Alliance 50202)MATRix / IELSG43 StudieUniversites Paris, Paris, France, LOC network studyProtocols in Revision 19 protocols foundProtocols under revision.Carmustine 400 / Thiotepa 5, consolidation before autologous Stem Cell Transplantation, CNS- Non-Hodgkin Lymphoma (PID890 V2.1)Cytarabine 2000 / Etoposide 5, CNS Lymphoma, cycle 6 (PID1866 V1.0)Methotrexate 8000 / Rituximab 375 / Temozolomide 150, CNS Lymphoma, cycle 1 (PID1859 V1.1)Methotrexate 8000 / Rituximab 375 / Temozolomide 150, CNS Lymphoma, cycle 2 (PID1860 V1.3)Methotrexate 8000 / Temozolomide 150, CNS Lymphoma, cycle 3 (PID1861 V1.3)Methotrexate 8000 / Temozolomide 150, CNS Lymphoma, cycle 4 (PID1864 V1.3)Methotrexate 8000 / Temozolomide 150, CNS Lymphoma, cycle 5 (PID1865 V1.3)Rituximab 375 / Carboplatin 300 / Ifosfamide 1.5 / Etoposide 100 / Dexamethasone 40, CNS- Non-Hodgkin Lymphoma, consolidation (PID831 V1.1)Rituximab 375 / Carmustine 400 / Thiotepa 5, CNS- Non-Hodgkin Lymphoma, conditioning, cycle 5 (PID1883 V1.0)Rituximab 375 / Cytarabine 3000 / Thiotepa 40, CNS- Non-Hodgkin Lymphoma, induction, cycle 3 (PID1881 V1.0)Rituximab 375 / Cytarabine 3000 / Thiotepa 40, CNS- Non-Hodgkin Lymphoma, Induction, Cycle 4 (PID1882 V1.0)Rituximab 375 / Cytarabine 3000, CNS- lymphoma, cycle 4-6 (PID1901 V1.0)Rituximab 375 / Methotrexate 3000 / Procarbazine 60 - Procarbazine 100, maintenance, CNS- Lymphoma (PID1031 V1.2)Rituximab 375 / Methotrexate 3000 / Procarbazine 60, CNS lymphoma, cycle 1 (PID1191 V1.3)Rituximab 375 / Methotrexate 3000 / Procarbazine 60, CNS- lymphoma, cycle 2-3 (PID1030 V2.3)Rituximab 375 / Methotrexate 3500 / Procarbazine 100 / Vincristine 2, CNS Lymphoma, cycle 1-3 (PID1896 V1.2)Rituximab 375 / Methotrexate 500/3000 / Cytarabine 2000 / Thiotepa 30, CNS- Non-Hodgkin Lymphoma, induction (PID703 V2.1)Rituximab 375 / Methotrexate 8000, CNS- Non-Hodgkin Lymphoma, induction, cycle 1 (PID1879 V1.2)Rituximab 375 / Methotrexate 8000, CNS- Non-Hodgkin Lymphoma, induction, cycle 2 (PID1880 V1.2)
